Jaypirca
What Jaypirca is used for
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Jaypirca
- Active substance
- pirtobrutinib
- Disease area
- Lymphoma, Mantle-Cell
- Medicine group
- Antineoplastic agents;Protein kinase inhibitors
- ATC code
- L01
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Jaypirca
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jaypirca used for?
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
What is the active substance in Jaypirca?
Jaypirca contains pirtobrutinib.
Who makes Jaypirca?
The EU marketing authorisation holder is Eli Lilly Nederland B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU